Venus Remedies gains on securing marketing authorization for chemotherapy drug 'Docetaxel'
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Venus Remedies is currently trading at Rs. 242.40, up by 4.30 points or 1.81% from its previous closing of Rs. 238.10 on the BSE.
The scrip opened at Rs. 239.65 and has touched a high and low of Rs. 246.75 and Rs. 231.00 respectively. So far 9561 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 263.55 on 31-May-2023 and a 52 week low of Rs. 145.00 on 08-Feb-2023.
Last one week high and low of the scrip stood at Rs. 263.55 and Rs. 194.95 respectively. The current market cap of the company is Rs. 322.08 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.00% and 57.24% respectively.
In a decisive step towards making its entire oncology product portfolio available in Saudi Arabia, Venus Remedies has secured a marketing authorization from the largest market in the Gulf Cooperation Council (GCE) region for Docetaxel, a widely used chemotherapy drug.
The development comes three months after the company received good manufacturing practices (GNP) certification from the Saudi Food and Drug Authority (SFDA) for all its production facilities at its unit in Baddi, Himachal Pradesh.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
